Focus Partners Advisor Solutions LLC Increases Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Focus Partners Advisor Solutions LLC increased its stake in Alnylam Pharmaceuticals by **216.0%**, acquiring an additional 1,862 shares, which raised their total ownership to 2,724 shares valued at **$736,000**.
• Insider sales include EVP Pushkal Garg selling 1,455 shares for about **$667,000**, and CEO Yvonne Greenstreet selling 6,979 shares for approximately **$3.16 million**, representing notable decreases in their ownership.
• Brokerage firms have raised their price targets for Alnylam Pharmaceuticals, with Scotiabank increasing their target from **$342** to **$450** and other firms also projecting significant upside for the stock.

Focus Partners Advisor Solutions LLC raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 216.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,724 shares of the biopharmaceutical company's stock after acquiring an additional 1,862 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Alnylam Pharmaceuticals were worth $736,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $243,000. Comerica Bank boosted its position in Alnylam Pharmaceuticals by 631.7% in the fourth quarter. Comerica Bank now owns 13,991 shares of the biopharmaceutical company's stock valued at $3,292,000 after buying an additional 12,079 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $612,000. Captrust Financial Advisors boosted its position in Alnylam Pharmaceuticals by 32.7% in the fourth quarter. Captrust Financial Advisors now owns 6,414 shares of the biopharmaceutical company's stock valued at $1,509,000 after buying an additional 1,581 shares in the last quarter. Finally, Brevan Howard Capital Management LP boosted its position in Alnylam Pharmaceuticals by 3.4% in the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock valued at $314,000 after buying an additional 44 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 3.9%

Alnylam Pharmaceuticals stock traded down $18.56 during midday trading on Wednesday, hitting $463.57. 698,123 shares of the stock were exchanged, compared to its average volume of 969,852. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21. The stock has a market capitalization of $60.76 billion, a price-to-earnings ratio of -187.46 and a beta of 0.32. The business's 50-day moving average price is $393.25 and its 200-day moving average price is $312.72. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,274 shares of the company's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the sale, the executive vice president owned 50,121 shares of the company's stock, valued at approximately $22,718,345.67. This represents a 4.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $632,764.92. Following the completion of the transaction, the executive vice president directly owned 22,719 shares of the company's stock, valued at approximately $10,297,841.13. This represents a 5.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,594 shares of company stock worth $25,551,456 in the last ninety days. Insiders own 1.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ALNY. Scotiabank raised their target price on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research report on Friday, August 1st. JPMorgan Chase & Co. raised their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 target price for the company. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Finally, Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research note on Friday, July 11th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $417.38.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.